References
- Hoeg JM. Familial hypercholesterolemia. What the zebra can teach us about the horse. JAMA 271, 543–546 (1994).
- Mabuchi H, Haba T, Tatami R et al. Effect of an inhibitor of 3‑hydroxy‑3‑methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone‑10‑levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478–482 (1981).
- Mabuchi H, Tatami R, Haba T et al. Homozygous familial hypercholesterolemia in Japan. Am. J. Med. 65, 290–297 (1978).
- Mabuchi H, Higashikata T, Kawashiri MA. Clinical applications of long‑term LDLapheresis on and beyond refractory hypercholesterolemia. Transfus. Apher. Sci. 30, 33–243 (2004).
- Kawagishi N, Satoh K, Akamatsu Y et al. Long‑term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. J. Atheroscler. Thromb. 14, 94–98 (2007).
- Wetterau JR, Aggerbeck LP, Bouma ME et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258(5084), 999–1001 (1992).
- Sharp D, Blinderman L, Combs KA et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365, 65–69 (1993).
- Yang XP, Inazu A, Yagi K et al. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. Arterioscler. Thromb. Vasc. Biol. 19(8), 1950–1955 (1999).
- Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148–156 (2007).
- Cuchel M, Meagher EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single‑arm, openlabel, Phase 3 study. Lancet 381, 40–46 (2013).
- Hewing B, Parathath S, Mai CK et al. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis 227, 125–129 (2013).
- Kim E, Campbell S, Schueller O et al. A small‑molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx‑4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J. Pharmacol. Exp. Ther. 337, 775–785 (2011).
- Hata T, Mera Y, Tadaki H et al. JTT‑130, a novel intestine‑specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet‑induced obesity and glucose intolerance in Sprague‑Dawley rats. Diabetes Obes. Metab. 13, 446–454 (2011).
- Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr. Opin. Lipidol. 24, 246–250 (2013).